Edwards data show benefit of early TAVR over ‘watchful waiting’

Edwards Lifesciences’ early TAVR trial results showed asymptomatic patients with severe aortic stenosis had better outcomes after transcatheter aortic valve replacement than under routine clinical surveillance.